The Critical Path for Parkinson’s 3DT initiative is focusing on a case study entitled WATCHPD which focuses on APDM opal sensors and a custom developed iPhone App to measure concepts of interest linked to both motor and nonmotor symptoms.

Measuring meaningful change in the progression of Parkinson’s disease (PD) in patients at very early stages of the disease.

The DiMe Measures that Matter framework confirmed that our scientific approach to the 3DT project – which was in progress when the DiMe resource launched – was very much aligned with best practices and industry-wide recommended approaches.

The framework articulates the need to align with patients early and often in design of clinical trials. It also aligns with terminology in the BEST Glossary, distinguishing Clinical Outcomes Assessment (COAs) from digital biomarkers. These are themes that continue to be confusing to the field yet are nicely outlined in the framework, helping us drive broad adoption of an approach to digital measure development that starts with the patient.

The WATCHPD study has collected over 4,100 hours of patient interview data to identify the most meaningful measures to patients. This is essential to ensuring that the digitization of healthcare helps redefine how we measure the symptoms of PD to speed the development of effective new therapies and improve our ability to monitor and manage the care of people with Parkinson’s.

---

**Critical Path Institute** is a catalyst in the development of new approaches to advance medical innovation and regulatory science.

*If we are ever going to get a handle on Parkinson’s we must consider the breadth of impairments and use digital techniques to collect data continuously. The CPP team has done a remarkable job in constructing a viable approach.*

— John Crawford, Biotech executive living with Parkinson’s, Critical Path Institute

---